SCHEMBL6718599

SCHEMBL6718599

Cc1ccc(-c2ccccc2)cc1NNC(=O)C(c1ccccc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.38
ALDH1A1 P00352 3/20 0.37
ACLY P53396 1/20 0.36
GAA P10253 1/20 0.35
HDAC1 Q13547 2/20 0.34
KDM4E B2RXH2 1/20 0.34
APOBEC3A P31941 1/20 0.34
GFER P55789 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
KMT2A Q03164 3/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC2 Q92769 1/20 0.34
BRD4 O60885 1/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715970 0.91 SLC1A3 (0.41) CASP2ALDH1A1GAAKDM4EKMT2A
SCHEMBL6715762 0.78 BRD4 (0.54) ALDH1A1KMT2ALMNASMN1; SMN2NPSR1
SCHEMBL6717373 0.77 CASP2 (0.45) CASP2ALDH1A1ACLYGAAHDAC1
SCHEMBL6716842 0.77 CYP1A2 (0.48) ALDH1A1GAALMNASMN1; SMN2NPSR1
SCHEMBL6716835 0.77 CYP1A2 (0.48) ALDH1A1GAALMNASMN1; SMN2NPSR1
SCHEMBL6821806 0.76 CASP2 (0.41) CASP2ALDH1A1ACLYGAAHDAC1
SCHEMBL6717139 0.74 GAA (0.46) ALDH1A1GAAKMT2ALMNASMN1; SMN2
SCHEMBL6715700 0.73 ALDH1A1 (0.43) ALDH1A1KDM4EKMT2ASMN1; SMN2HTT
SCHEMBL6723447 0.73 KMT2A (0.50) ALDH1A1GAAKMT2ALMNASMN1; SMN2
SCHEMBL6719501 0.72 MAPT (0.46) ALDH1A1KMT2ALMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 CASP2 4021/4885ALDH1A1 572/4885ACLY 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.